WO2017219951A1 - Récepteur de l'epo et son application dans un carcinome hépatocellulaire avec la polycythémie - Google Patents

Récepteur de l'epo et son application dans un carcinome hépatocellulaire avec la polycythémie Download PDF

Info

Publication number
WO2017219951A1
WO2017219951A1 PCT/CN2017/089099 CN2017089099W WO2017219951A1 WO 2017219951 A1 WO2017219951 A1 WO 2017219951A1 CN 2017089099 W CN2017089099 W CN 2017089099W WO 2017219951 A1 WO2017219951 A1 WO 2017219951A1
Authority
WO
WIPO (PCT)
Prior art keywords
epor
epo
liver cancer
signaling pathway
cells
Prior art date
Application number
PCT/CN2017/089099
Other languages
English (en)
Chinese (zh)
Inventor
王红阳
文文
柯仕忠
陈淑桢
董子慧
唐亮
凌妍
Original Assignee
中国人民解放军第二军医大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中国人民解放军第二军医大学 filed Critical 中国人民解放军第二军医大学
Publication of WO2017219951A1 publication Critical patent/WO2017219951A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention relates to the technical field of tumor treatment, in particular to an EPO receptor (EPOR) and its application in hepatocellular carcinoma with erythrocytosis.
  • EPO receptor EPO receptor
  • liver cancer is a common clinical malignant tumor, and Hepatocellular Carcinoma (HCC) is the most important pathological type.
  • WHO World Health Organization
  • liver cancer is the fifth most common tumor in men and ranks ninth among women's common tumors.
  • WHO World Health Organization
  • liver cancer is the fifth most common tumor in men and ranks ninth among women's common tumors.
  • the incidence of liver cancer has increased due to the increase in the incidence of underlying diseases such as HCV infection and steatohepatitis.
  • liver cancer The cause of liver cancer is complicated, the degree of malignancy is high, and the heterogeneity is strong, and most patients are found to be advanced, often with a poor prognosis. In developed countries such as Europe and the United States, the 5-year survival rate is also less than 15% (Czaja, M.J., Factors of autophagy in hepatic and pancreatic physiology and disease. Gastroenterology, 2011.140(7): p. 1895-908.).
  • the current treatment strategy for liver cancer is a combination of radical surgery and palliative care guided by a staging system (Kroemer, G., G. Marino, and B. Levine, Autophagy and the integrated stress response.
  • liver cancer malignant tumors including liver cancer are a very complicated disease.
  • the pathological process involves the abnormal regulation of a series of molecular pathways, and there is obvious heterogeneity between patients, even the same patient tumor.
  • liver cancer difficult to explain with a single model. Therefore, the molecular level of liver cancer from the abnormal expression of different molecular levels and signaling pathways is crucial for the individualized treatment of liver cancer (Mizushima, N. and M. Komatsu, Autophagy: renovation of cells and tissues. Cell, 2011.147(4): p. 728-41.).
  • Polycythemia is a relatively common syndrome with cancer, which is associated with approximately 3%-12% of patients with hepatocellular carcinoma (Jacobson RJ, Lowenthal MN, and Kew MC. Erythrocytosis in hepatocellular cancer. S Afr Med J.1978; (17): 658-60).
  • polycythemia was found in many malignant tumors, such as kidney cancer, meningioma (Hammond D, and Winnick S. Paraneoplastic erythrocytosis and ectopic erythropoietins. Ann N Y Acad Sci.
  • erythrocytosis is mainly caused by increased production of erythropoietin (EPO) in cancer tissues (Matsuyama M, Yamazaki O, Horii K, Higaki I, Kawai S, Mikami S, Higashino M, Oka) H, Nakai T, and Inoue T. Erythrocytosis caused by an erythropoietin-producing hepatocellular carcinoma. J Surg Oncol.
  • EPO is a pleiotropic cytokine in erythropoiesis , angiogenesis, cell proliferation and other processes have a certain role
  • EPOR belongs to cytokine receptor Members of the superfamily, mainly expressed on hematopoietic precursor cells (Bunn HF. Erythropoietin. Cold Spring Harbor Perspectives in Medicine. 2013; 3 (3). Jelkmann W, Bohlius J, Hallek M, and Sytkowski AJ. The erythropoietin Receptor in normal and cancer tissues. Crit Rev Oncol Hematol. 2008;67(1):39-61.).
  • EPOR is a dimer in the absence of hormonal effects. Each dimer constitutively binds to a JAK-2 tyrosine kinase molecule.
  • EPO binds to EPOR and induces a conformational change in EPOR, which is activated by the phosphorylation of JAK2.
  • Cascade signal transduction leads to cell proliferation, survival and differentiation (Bunn HF. Erythropoietin. Cold Spring Harbor Perspectives in Medicine. 2013; 3(3).).
  • EPOP is co-expressed with human epidermal growth factor receptor-2 (HER2) in a large proportion of breast cancer samples and breast cancer cell lines.
  • EPO promotes breast cancer formation by promoting the ability of tumor precursor cells to self-renew (Zhou B, Damrauer JS, Bailey ST, Hadzic T, Jeong Y, Clark K, Fan C, Murphy L, Lee CY, Troester MA, et al. Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal. J Clin Invest. 2014; 124(2): 553-63.).
  • Combination therapy with this type of breast cancer with human recombinant EPO can reduce the response of tumor cells to trastuzumab, and the combined tumor suppression time in HER-2 positive metastatic breast cancer is shorter, and the overall survival time of patients is also more Short (Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, Yang CY, Li Y, Li X, Chen CT, et al.Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2- Mediated Src activation and PTEN inactivation. Cancer Cell. 2010; 18(5): 423-35).
  • EPO or EPOR has limited research reports on the progression of hepatocellular carcinoma.
  • Some literatures suggest that the expression of EPO/EPOR in hepatocellular carcinoma is related to angiogenesis and progression of hepatocellular carcinoma, and its effect may be through liver cancer cells.
  • the paracrine form of EPOR which secretes EPO to act on vascular endothelial cells, promotes angiogenesis (Ribatti D, Marzullo A, Gentile A, Longo V, Nico B, Vacca A, et al. Erythropoietin/erythropoietin-receptor system is involved in angiogenesis In human hepatocellular carcinoma. Histoathology 2007; 50(5): 591-6.).
  • the article does not explore its mechanism of action further and is limited to EPO.
  • the role of vascular endothelial cells was discussed and its effect on liver cancer cells and other related mesenchymal cells was not explored. All patients selected in this study were negative for HbsAg, and the study population did not meet the characteristics of most HCC patients with HbsAg positive in China.
  • the study was conducted on the differentiation of liver cancer patients, not in the study of liver cancer with polycythemia. Such patients. Therefore, there is no literature on the relationship between EPO and liver cancer with erythrocytosis in liver cancer, and there is no report on the treatment of hepatocellular carcinoma with erythrocytosis by blocking EPOR.
  • the present invention performs genome-wide and mtDNA sequencing of cancer tissues and adjacent normal tissues of hepatocellular carcinoma accompanying polycythemia, and finds that mitochondrial mutations in these liver cancer samples can cause metabolites in the tricarboxylic acid cycle to be deleted, resulting in accumulation of HIF. .
  • the increased formation of HIF can induce the expression of a large amount of EPO in hepatocellular carcinoma, causing polycythemia, which leads to the progression of liver cancer.
  • the extracellular Fc fusion protein of EPOR can block the EPO/EPOR signaling pathway, which can significantly induce apoptosis and inhibit tumor growth by in vitro and in vivo experiments. All of the above findings indicate that polycythemia caused by EPO production in hepatocellular carcinoma promotes the progression of hepatocellular carcinoma, and suggests that blocking EPO/EPOR signaling pathway may serve as a new therapeutic target for such liver cancer.
  • an EPO/EPOR signaling pathway inhibitor or blocker for the preparation of a medicament for treating liver cancer with polycythemia.
  • the EPO/EPOR signaling pathway inhibitor or blocker inhibits tumor cell proliferation, induces apoptosis, and inhibits tumor growth.
  • the EPO/EPOR signaling pathway inhibitor or blocker is an inhibitor of EPO or EPOR.
  • the EPO/EPOR signaling pathway inhibitor is a JAK2 inhibitor, which may be AZD1480 or the like.
  • the EPO/EPOR signaling pathway inhibitor or blocker is an EPOR extracellular Fc fusion protein.
  • the EPO/EPOR signaling pathway inhibitor or blocker is a recombinant vector or adenovirus expressing an EPOR extracellular Fc fusion protein.
  • the EPO/EPOR signaling pathway inhibitor or blocker is a recombinant adenovirus Ad-EPOR-Fc that expresses an EPOR extracellular Fc fusion protein.
  • the Ad-EPOR-Fc consists of an adenoviral vector, an EPOR extracellular segment template sequence (SEQ ID NO: 1) and a human immunoglobulin Fc segment template sequence (SEQ ID NO: 2), constructed by DNA recombination technology.
  • the plasmid was assembled into an infectious adenovirus particle by 293A cells with an adenoviral backbone plasmid.
  • the expressed EPOR receptor Fc-segment fusion protein (EPOR-Fc) is a domain that binds to EPO on EPOR, and the synthesis and expression of this protein in eukaryotic cells can block the EPO/EPOR signaling pathway.
  • a liver cancer drug for treating erythrocytosis wherein the active ingredient of the liver cancer drug for treating erythrocytosis is an EPO/EPOR signaling pathway inhibitor or a blocking agent.
  • the present inventors have found that polycythemia caused by the production of EPO in hepatocellular carcinoma promotes the progression of hepatocellular carcinoma, and the present invention proposes that inhibition or blocking of the EPO/EPOR signaling pathway can be a new therapeutic target for such liver cancer.
  • the recombinant adenovirus Ad-EPOR-Fc and the recombinant protein EPOR-Fc of the invention can significantly inhibit the proliferation of cells, down-regulate the expression level of p-stat3, and have no obvious toxicity to normal liver cells, compared with other commercial recombinant receptors.
  • the treatment effect of liver cancer with erythrocytosis is more significant, providing new ideas and methods for the treatment of liver cancer.
  • Figure 1 shows the content of EPO in serum of liver cancer patients (red) and ordinary liver cancer patients (blue) with erythrocytosis by ELISA.
  • Fig. 2 is a graph showing the expression level of EPO in tumor tissues of liver cancer patients (red) and ordinary liver cancer patients (blue) with erythrocytosis by RT-PCR.
  • Figure 3 is a subpopulation of EPOR positive cells in the PDX model by flow cytometry, in which the amount of EPCAM expression is higher.
  • Figure 4 is a graph showing the expression levels of stem cell markers in a subset of EPOR positive and negative cells in a PDX model by flow cytometry.
  • the expression levels of tumor precursor cell markers in the two groups were detected by RT-PCR.
  • the expression levels of OCT4, SOX9, LGR5, NANOG and CD133 in EPOR high expression cells were significantly higher than those in EPOR negative cells.
  • Figure 5 is a diagram showing that the soluble EPOR extracellular domain expressed by adenovirus Ad-EPOR-Fc can bind to EPO, thereby blocking EPO binding to EPO on the cell membrane, and blocking the pattern of the intracellular signaling pathway of EPO.
  • Figure 6 is a graph showing the proliferation of cells after treatment with Huh7 cells with Ad-GFP and Ad-EPOR-Fc, respectively. The cell proliferation was significantly slower than that of the control cells within 72 h after treatment of Huh7 by Ad-EPOR-Fc as shown.
  • Figure 7 is a graph comparing tumor size after one month of treatment of EPOR high expression of PDX with Ad-EPOR-Fc and control adenovirus in an in vivo experiment. After one month of inoculation of EPO-overexpressing PDX mice with Ad-EPOR-Fc and control adenovirus tail veins, the figure showed that the tumor size after Ad-EPOR-Fc treatment was significantly smaller than that of the control group.
  • Figure 8 is a graph showing the fluorescence of Ad-EPOR-Fc and control adenovirus-treated Huh7 cells as well as primary isolated normal hepatocytes. The figure shows that Ad-EPOR-Fc can significantly inhibit the proliferation of Huh7 cells compared with the control adenovirus, but has no obvious toxicity to the primary isolated normal liver cells.
  • Figure 9 is the expression level of p-stat3 after Huh7 cells were treated with WB to detect Ad-EPOR-Fc and control adenovirus. The figure shows that the expression level of p-stat3 was significantly lower in the Huh7 cells treated with Ad-EPOR-Fc than in the control group.
  • FIG. 10 is a diagram showing the expression of p-stat3 in cell lysates after infection of Ad-GFP and Ad-EPOR-Fc with EPO and EPOR-expressing hepatoma cell line Huh7 for 24 hours.
  • Huh7 cells infected with Ad-EPOR- After Fc the expression level of p-stat3 was significantly down-regulated compared to the control.
  • Figure 11 is a graph showing the proliferation coefficient of Huh7 cells treated with different concentrations of the competitive JAK2 inhibitor AZD1480 for 100 hours.
  • A1/A2 is the control group
  • B1/B2 is the AZD1480 2uM treatment group
  • C1/C2 is the AZD1480 4uM treatment group
  • D1/D2 is the AZD1480 8uM treatment group.
  • Figure 12 is a graph showing the proliferation coefficient of primary isolates of PDX tumor cells treated with different concentrations of the competitive JAK2 inhibitor AZD1480 for 100 hours.
  • A1/B1 is the control group
  • F1/F2 is the AZD1480 2uM treatment group
  • G1/G2 is the AZD1480 4uM treatment group
  • H1/H2 is the AZD1480 8uM treatment group.
  • Figure 13 is a diagram showing the identification of a cloned target gene of an adenovirus Ad-EPOR-Fc PCR clone expressing a recombinant soluble EPO receptor Fc fragment fusion protein.
  • Figure 14 is a diagram showing the construction of adenovirus Ad-EPOR-Fc PCR expressing recombinant Fc fragment fusion protein of recombinant soluble EPO receptor, and the restriction endonuclease digestion of Fermentas restriction endonuclease EcoRI/BamHI .
  • Figure 15 shows the recombinant adenovirus Ad-EPOR-Fc PCR-expressing clones expressing the recombinant soluble EPO receptor Fc-segment fusion protein.
  • the clones were cloned with primers Ad8-F and R for PCR verification.
  • the target band size is shown in the figure. Prove that all three clones were positive.
  • Example 1 High expression of EPO detected in serum and tumor tissues of liver cancer patients with erythrocytosis
  • liver cancer patients with liver cancer, adjacent tissues and serum samples were obtained from the Eastern Hepatobiliary Surgery Hospital. Eight patients with liver cancer who were diagnosed with erythrocytosis were included in the study. The sample was tested with the Human EPO Platinum ELISA kit (eBioscience). Serum EPO levels were significantly higher than the control group and the upper limit of the reference value (35 mU / mL), the results of the ELISA test are shown in Figure 1. The EPO mRNA levels in the control group and the hepatocarcinoma tissues with erythrocytosis were detected by RT-PCR, and it was confirmed that the EPO expression level was increased in patients with elevated EPO levels in the serum compared with the control group.
  • Sample RNA extraction Collect liver cancer and paracancerous tissues of patients with liver cancer after operation. Add the appropriate amount of TRIZON (100mg tissue, 1ml) to the above tissue, and fully lyse it with a homogenizer. Add 1/5 of chloroform in Trizol volume and shake vigorously.
  • RNAsin 1ul take 2ug of RNA, add 2ul of N6 random primer and appropriate amount of Q water, adjust the total volume to 14ul, and sip for 5 minutes on the ice at 5°C for 7 minutes.
  • the 37-degree water bath was used for 1 h, and the obtained cDNA was cDNA.
  • reaction system 20ul: SYBR Green PCR Master Mix (Roche) 10ul, primer 10ul, cDNA 1ul and Q water 8ul, return temperature is 60 ° C, according to the machine
  • the reaction conditions were set for PCR reaction, and the detection primers for EPO were:
  • Upstream primer 5'-ATCACGACGGGCTGTGCTGAACAC-3' (SEQ ID NO: 3)
  • the mRNA level of EPO was normalized with ⁇ -actin.
  • PDX tumor cells were isolated from primary cells, and EPO positive and negative hepatoma cells were enriched in PDX model mice by magnetic separation technique. EPOR was detected by flow cytometry. Positive cells showed higher expression of Epcam compared to control cells (Fig. 3).
  • RT-PCR was used to detect the expression levels of tumor precursor cell markers in the two groups of cells. It was found that the expression levels of OCT4, SOX9, LGR5, NANOG and CD133 in EPOR high expression cells were significantly higher than those in EPOR negative cells (Fig. 4).
  • liver cancer cells The primary separation and magnetic separation steps of liver cancer cells are as follows:
  • the cell suspension is added to a magnetic sorting column, and the filtered cells in the column are collected in a 1.5 ml EP tube to be EPOR-negative cells;
  • RT-PCR reaction system and conditions are the same as before, and the primer sequences used are as follows:
  • Example 3 Construction of Ad-EPOR-Fc and verification of its inhibition of proliferation of hepatoma cells
  • adenovirus Ad-EPOR-Fc expressing a fusion protein of recombinant soluble EPO receptor Fc fragment was constructed.
  • the recombinant plasmid construction method of adenovirus is as follows:
  • the whole gene was synthesized into the target gene fragment EPOR (the most upstream with the EcoRI restriction site), and the two segments were used to bridge the epr1-10 and epr11-20, and the plasmid PIH (with the FC gene fragment) was used as a template, and the primer fcf/r PCR was carried out, and the gene FC (681 bp, with the BamHI restriction site at the bottom) was cloned, and the above three gene fragments were spliced and bridged, and the full-length target gene EPOR-FC was amplified by primer exr1/fcf.
  • the cloned fragment identification map is shown in Figure 13.
  • the double-digested gene fragment (product directly purified) and the vector Ad8 (purified by gel) were subjected to Fermentas restriction enzyme EcoRI/BamHI, and the identification map is shown in Fig. 14.
  • the vector and the fragment were ligated by T4 DNA ligase, and the recombinant vector was transformed into the host strain TOP10, and the transformed product was spread on an Amp-resistant plate, and cultured overnight at 37 ° C, and about 300 clones were grown on the plate.
  • the clones were picked for primers Ad8-F and R for PCR verification. The size of the target bands is shown in Figure 15. All three clones were positive, and positive clones were sent for sequencing.
  • the extracellular segment of soluble EPOR expressed by adenovirus Ad-EPOR-Fc can bind to EPO, thereby blocking EPO binding to EPO and blocking the intracellular signaling pathway of EPO.
  • the adenovirus blocked the function of pathologically elevated EPO in the Huh7 cell line, and cell proliferation was detected by CCK8, and it was found that Ad-EPOR-Fc significantly inhibited cell proliferation compared to the control (Fig. 6).
  • EPO high-expressing PDX mice were inoculated with Ad-EPOR-Fc and control adenovirus tail vein, virus volume: 10 8 pfu/only, once every two weeks, mice were sacrificed after tumor formation, and tumor measurement volume was taken out. Size and photographing showed that the tumor size of the Ad-EPOR-Fc treatment group was significantly smaller than that of the control group (Fig. 7).
  • Ad-EPOR-Fc Normal liver primary cells and Huh7 cells were inoculated into 96-well plates, Ad-EPOR-Fc was used to infect primary liver cells and Huh7 cells, and Ad-GFP was used as control virus. After 24 hours of infection, cell morphology was observed by fluorescence microscope. Compared with the control adenovirus, Ad-EPOR-Fc can significantly inhibit the proliferation of Huh7 cells, but has no obvious toxicity to the primary isolated normal liver cells (Fig. 8).
  • EPOR-Fc is more effective than other commercialized receptor-recombinant proteins for the treatment of liver cancer with erythrocytosis
  • the EPO and EPOR-expressing hepatoma cell line Huh7 were used to infect Ad-GFP and Ad-EPOR-Fc, and 1 ⁇ 10 6 Huh7 cells were seeded in 6-well plates.
  • the MOI value was 10: after 24 hours of culture, washed with physiological saline.
  • IP lysate Appropriate amount of IP lysate; fully lysed on ice for 15min-30min, ultrasonically disrupted cells on ice (30% intensity, 3-5 seconds / time, interval 3-5 seconds, total 3-5 times), 4 ° C, 12,000 rpm, Centrifuge for 15-30min, transfer the supernatant to a new EP tube; BCA protein quantification kit for protein quantification; use a multi-plate reader for protein quantification, obtain the protein concentration of each sample, take an equal amount of protein sample (cell sample taken 40ug), adjusted to the same volume of each sample with IP lysate, then add 1/3 of this volume of 4 ⁇ SDS loading buffer; 100°C honeycomb furnace, denaturing sample for 5min and then placed on ice for more than 2min; sample in the order of setting 1 ⁇ Tris-glycine was subjected to SDS-PAGE protein electrophoresis for 3-4 h; the protein was transferred to a nitrocellulose membrane (NC membrane) by a wet transfer film transfer machine
  • the NC membrane was blocked at room temperature for 1 h (slow shaking on a hybrid shaker); 1 ⁇ TBST was washed 3 times for 5 min each; Pour 5% BSA to dilute the primary antibody.
  • the specific information of the antibody is as follows: Stat3 (124H6) Mouse mAb, Cat#9139 (Cell Signaling Technology), Phospho-Stat3 (Tyr705) (D3A7) Rabbit mAb, Cat#9145 (Cell Signaling Technology), Beta-Actin Antibody, Rabbit pAb, Cat#100162-RP02-50 (Sino Biological Inc.); Incubate the NC membrane slowly at room temperature on a hybrid shaker for 2-3 h; ⁇ TBST was washed 3 times for 5 min each time; 5% BSA diluted fluorescent secondary antibody was incubated for 1.5-2 h at room temperature; 1 ⁇ TBST was washed 3 times for 5 min each time (protected from light); Odyssey fluorescence scanner was used to scan the membrane. As shown in Figure 10, Huh7 cells were
  • Example 7 Cellular pathway JAK inhibitor significantly inhibits proliferation of hepatoma cells with polycythemia
  • the E-Plate VIEW 16-well plate was incubated with the medium for 30 minutes, and 4000 Huh7 cells were seeded per well. After the cells were attached, a competitive JAK2 inhibitor AZD1480 (selleck) was added to set a concentration gradient of 2 ug/ml, 4 ug/ Mp and 8 ug/ml, the control was normal saline, and the cell proliferation was monitored by RTCA (ACEA Bioscience) in real time for 100 hours.
  • the cell proliferation coefficient is shown in Fig. 11.
  • the primary PDX tumor cells were isolated and inoculated with 10000 cells per well. The above experiment was repeated after the cells were attached.
  • the cell proliferation coefficient is shown in Figure 12.
  • the cell pathway JAK inhibitor significantly inhibited the proliferation of hepatoma cells with polycythemia. effect.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne une application d'un inhibiteur ou bloqueur de la voie de signalisation de l'EPO/EPOR dans la préparation de médicaments destinés au traitement du carcinome hépatocellulaire avec la polycythémie. La polycythémie provoquée par la génération d'EPO dans le carcinome hépatocellulaire facilite le développement du carcinome hépatocellulaire, et l'inhibition ou le blocage de la voie de la signalisation de l'EPO/EPOR peut être utilisée en tant que nouvelle cible thérapeutique d'un tel carcinome hépatocellulaire. L'adénovirus recombinant Ad-EPOR-Fc et la protéine recombinante EPOR-Fc peuvent évidemment inhiber la prolifération de cellules cancéreuses et diminuer le niveau d'expression de p-stat3, et n'ont aucune toxicité évidente vis-à-vis des cellules hépatiques normales, fournissant ainsi une nouvelle idée et un procédé pour le traitement du carcinome hépatocellulaire.
PCT/CN2017/089099 2016-06-24 2017-06-20 Récepteur de l'epo et son application dans un carcinome hépatocellulaire avec la polycythémie WO2017219951A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610470816.XA CN106075447B (zh) 2016-06-24 2016-06-24 一种epo受体及其在伴红细胞增多症的肝细胞癌中的应用
CN201610470816.X 2016-06-24

Publications (1)

Publication Number Publication Date
WO2017219951A1 true WO2017219951A1 (fr) 2017-12-28

Family

ID=57253455

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/089099 WO2017219951A1 (fr) 2016-06-24 2017-06-20 Récepteur de l'epo et son application dans un carcinome hépatocellulaire avec la polycythémie

Country Status (2)

Country Link
CN (1) CN106075447B (fr)
WO (1) WO2017219951A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106075447B (zh) * 2016-06-24 2018-07-10 中国人民解放军第二军医大学 一种epo受体及其在伴红细胞增多症的肝细胞癌中的应用
CN111175519B (zh) * 2020-01-09 2020-11-27 浙江大学 Epo在制备肝细胞癌tace疗效评估试剂中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106075447A (zh) * 2016-06-24 2016-11-09 中国人民解放军第二军医大学 一种epo受体及其在伴红细胞增多症的肝细胞癌中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL124015A0 (en) * 1998-04-08 1999-01-26 Yeda Res & Dev Pharmaceutical compositions comprising a protein
FR2823220B1 (fr) * 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
CN105542006A (zh) * 2015-12-11 2016-05-04 北京大学第一医院 抗epor融合蛋白抗体的制备方法和用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106075447A (zh) * 2016-06-24 2016-11-09 中国人民解放军第二军医大学 一种epo受体及其在伴红细胞增多症的肝细胞癌中的应用

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
KE , S. Z.: "Erythrocytosis in Hepatocellular Carcinoma Portends Poor Pro- gnosis by Respiratory Dysfunction Secondary to Mitochondrial DNA Mutations", HEPATOLOGY, vol. 65, no. 1, 24 October 2016 (2016-10-24) - 31 January 2017 (2017-01-31), pages 134 - 151, XP055601948, ISSN: 0270-9139, DOI: 10.1002/hep.28889 *
LI MEI ET AL.: "Research advances in Expression and functions of erythropoietin and erythropoietin receptor in cancers", CHINESE JOURNAL OF CANCER, vol. 27, no. 6, 5 June 2008 (2008-06-05), pages 667 - 672 *
MASTROGIANNAKI, M.: "Hepatic HIF-2 down-regulates hepcidin expression in mice through EPO -mediated increase in erythropoiesis", HAEMATOLOGICA, vol. 97, no. 6, 29 December 2011 (2011-12-29), pages 827 - 834 *
RIBATTI, D.: "Erythropoietin / erythropoietin-receptor system is involved in angiogenesis in human hepatocellular carcinoma", HISTOPATHOLOGY, vol. 50, no. 5, 26 March 2007 (2007-03-26), pages 591 - 596 *
TAM, B. Y. Y.: "VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis", NATURE MEDICINE, vol. 12, no. 7, 25 June 2006 (2006-06-25), pages 793 - 800, XP055188501, DOI: doi:10.1038/nm1428 *
YIN HAO ET AL.: "Research progress on primary hepatic carcinoma paraneoplastic syndrome", CHINESE JOURANL OF PRACTICAL SURGERY, vol. 30, no. 4, 30 April 2010 (2010-04-30), pages 321 - 326 *

Also Published As

Publication number Publication date
CN106075447A (zh) 2016-11-09
CN106075447B (zh) 2018-07-10

Similar Documents

Publication Publication Date Title
Zhang et al. AT-533, a novel Hsp90 inhibitor, inhibits breast cancer growth and HIF-1α/VEGF/VEGFR-2-mediated angiogenesis in vitro and in vivo
Polosa et al. Expression of c-erbB receptors and ligands in human bronchial mucosa
CN105435228B (zh) 三氧化二砷的抗肿瘤新用途及抗肿瘤制剂
CN103347520A (zh) 用作癌症化学治疗的晚期sv40因子（lsf）的抑制剂
WO2016197592A1 (fr) Utilisation d'un arn long non codant, hnf1a-as1, dans la préparation d'un médicament destiné au traitement d'une tumeur solide maligne humaine
CN111154869B (zh) 肝癌诊断的生物标志物及其试剂盒
Yin et al. Tongxinluo attenuates myocardiac fibrosis after acute myocardial infarction in rats via inhibition of endothelial‐to‐mesenchymal transition
Yang et al. MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs
CN113633758A (zh) 一种负载膜结合型肿瘤坏死因子相关凋亡诱导配体和小分子抗肿瘤药物的复合外泌体
WO2017219951A1 (fr) Récepteur de l'epo et son application dans un carcinome hépatocellulaire avec la polycythémie
KR20200119538A (ko) 간암의 예방 또는 치료용 조성물
CN112656795A (zh) 防己诺林碱在抗结膜黑色素瘤中的作用机制及应用
Zhao et al. Metformin reduces pancreatic cancer cell proliferation and increases apoptosis through MTOR signaling pathway and its dose-effect relationship.
WO2013063874A1 (fr) Anticorps monoclonal contre le carcinome humain du poumon non à petites cellules et utilisation associée
WO2020073630A1 (fr) Utilisation du non-codage à chaîne longue dans la détection du cancer de la tête et du cou et l'inversion de la résistance tumorale
Xiao et al. Flavokawain A suppresses the vasculogenic mimicry of HCC by inhibiting CXCL12 mediated EMT
Guo et al. RUNX1 promotes liver fibrosis progression through regulating TGF‐β signalling
WO2019237688A1 (fr) Application de la protéine de niemann-pick c1 dans le diagnostic et le traitement du cancer
CN105521482B (zh) 联合应用HNF1α、HNF4α、FOXA3诱导分化治疗肝细胞癌
WO2021075559A1 (fr) Inhibiteur de croissance cellulaire ou inducteur de mort cellulaire pour fibroblastes associés au cancer
CN113773368B (zh) 一种foxm1拮抗多肽及其衍生物与应用
JP5579699B2 (ja) 分子標的薬に対する感受性が低下している癌の治療薬および分子標的薬に対する感受性を増強する医薬組成物
Guan et al. LncRNA HIF1A-AS2 modulated by HPV16 E6 regulates apoptosis of cervical cancer cells via P53/caspase9/caspase3 axis
CN111035752B (zh) 家蚕抗菌肽Cecropin A在食道癌治疗中的用途
WO2021243797A1 (fr) Utilisation de la protéine hsp22 de drosophila melanogaster dans la préparation d'un médicament antitumoral

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17814689

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17814689

Country of ref document: EP

Kind code of ref document: A1